Evaluation of the Efficacy and Tolerability of Bedaquiline in Drug-Resistant Tuberculosis
Hitesha H Trivedi, Suraj Tripathi, Parth Patel, Mittal C Balat, Mohmed Sohel Shaikh, Nilesh Patil · 2026
Read Evaluation of the Efficacy and Tolerability of Bedaquiline in Drug-Resistant Tuberculosis by Hitesha H Trivedi, Suraj Tripathi, Parth Patel, Mittal C Balat, Mohmed Sohel Shaikh, Nilesh Patil (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13630714.txt.
Description
Hitesha H Trivedi and five co-authors judge a key drug for drug-resistant tuberculosis. Their 2026 study follows patients on bedaquiline-based treatment in India. Resistant tuberculosis leaves few working drug options. Bedaquiline anchors modern regimens, so its real-world record matters.
Sixty-four patients at one hospital clinic were followed month by month from 2024 into 2025. Sputum tests turned negative in about ninety-five percent of them. All carried germs resistant to rifampicin, the classic first drug. Most isolates still answered to injectable drugs. The team tracked side effects, lab values, and pill-taking faithfully. Conversion did not hinge on age or other traits. The drug held up well in routine care.
Catalog record
| CREATOR | Hitesha H Trivedi, Suraj Tripathi, Parth Patel, Mittal C Balat, Mohmed Sohel Shaikh, Nilesh Patil |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 30 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |